Advanced search
Publication Cover
Postgraduate Medicine Volume 134, 2022 - Issue 7
Submit an article Journal homepage
857
Views
1
CrossRef citations to date
0
Altmetric
Clinical Features - Editorial

Therapeutic advances in guideline‐directed medical therapy for heart failure: the idealistic versus the pragmatic truth for vulnerable patients

Shannon Jonesa Inpatient Pharmacy, University Health Truman Medical Center, Kansas City, MO, USA
&
Angel Lopez-Candalesb Cardiovascular Medicine Division, University Health Truman Medical Center, University of Missouri-Kansas City, Kansas City, MO, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0019-651X
ORCID Icon
Pages 641-643 | Received 07 Mar 2022, Accepted 04 Aug 2022, Published online: 11 Aug 2022

References

  • Maddox TM, Januzzi JL, Allen LA, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol. 2021;77(6):772–810.
  • Straw S, McGinlay M, Witte KK. Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart. 2021Mar;8(1):e001585. PMID: 33653703; PMCID: PMC7929859.
  • Urbich M, Globe G, Pantiri K, et al. A systematic review of medical costs associated with heart failure in the USA (2014–2020). PharmacoEconomics. 2020;38(11):1219–1236.
  • Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596. DOI: 10.1161/CIR.0000000000000757.
  • Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068–3072.
  • Heidenreich PA, Albert NM, Allen LA, et al. American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–619.
  • Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397–1402.
  • Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996–1004.
  • Sacubitril and Valsartan. Lexi-Drugs. Lexi-Comp, Inc; Updated 2022 Jan 28.
  • Lisinopril. Lexi-Drugs. Lexi-Comp, Inc; Updated 2022 Feb 23.
  • Losartan. Lexi-Drugs. Lexi-Comp, Inc; Updated 2022 Feb 26.
  • Metoprolol Succinate. Lexi-Drugs. Lexi-Comp, Inc; Updated 2022 Feb 22.
  • Furosemide. Lexi-Drugs. Lexi-Comp, Inc; Updated 2022 Feb 26.
  • Empagliflozin. Lexi-Drugs. Lexi-Comp, Inc; Updated 2022 Feb 8.
  • Dapagliflozin. Lexi-Drugs. Lexi-Comp, Inc; Updated 2022 Jan 28.
  • Spironolactone. Lexi-Drugs. Lexi-Comp, Inc; Updated 2022 Feb 26.
  • Hydralazine. Lexi-Drugs. Lexi-Comp, Inc; Updated 2022 Feb 1.
  • Isosorbide Dinitrate. Lexi-Drugs. Lexi-Comp, Inc; Updated 2022 Jan 26.
  • Ivabradine. Lexi-Drugs. Lexi-Comp, Inc; Updated 2022 Feb 21.
  • McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
  • Avialable from: https://www.ajmc.com/view/heart-failure-coverage-success-seen-in-medicaid-expansion-states
  • McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
  • Fendrick AM, Djatche L, Pulungan Z, et al. Out-of-pocket payments for part d covered medications by medicare fee-for-service beneficiaries with heart failure with reduced ejection fraction. Am Heart J. 2022;246:74–81.
  • Vincent Rajkumar S. The high cost of prescription drugs: causes and solutions. Blood Cancer J. 2020 Jun 23;10(6):71. PMID: 32576816; PMCID: PMC7311400.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.